Takeda, Prometheus roll out CDPATH to predict Crohn’s Disease complications
Japanese biopharmaceutical company Takeda, in partnership with US-based diagnostics company Prometheus Laboratories, has rolled out the CDPATH programme in the US. CDPATH is a personalised prognostic test that